The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
 
Sagar Lonial
Stock and Other Ownership Interests - TG Therapeutics
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen Oncology; Merck; Novartis; Sanofi; Takeda
Research Funding - Bristol-Myers Squibb; Celgene; Takeda
Other Relationship - TG Therapeutics
 
HANG QUACH
Consulting or Advisory Role - Amgen; Antengene; Bristol-Myers Squibb/Celgene; Celgene; CSL Behring; GlaxoSmithKline; Janssen-Cilag; Karyopharm Therapeutics; Pfizer; Roche; Sanofi
Research Funding - Amgen; Bristol-Myers Squibb/Celgene; Celgene; GlaxoSmithKline; Karyopharm Therapeutics; Sanofi
 
Meletios A. Dimopoulos
Honoraria - Amgen; Beigene; Bristol-Myers Squibb; Janssen-Cilag; Sanofi; Takeda
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Janssen-Cilag; Sanofi; Takeda
 
Paula Rodríguez-Otero
Honoraria - Abbvie; Celgene; GlaxoSmithKline; H3 Biomedicine; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; BMS; GlaxoSmithKline; Janssen; Pfizer; Sanofi
Speakers' Bureau - BMS; GlaxoSmithKline; Janssen; Sanofi
Travel, Accommodations, Expenses - Pfizer
 
Jesus G. Berdeja
Consulting or Advisory Role - Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); crispr therapeutics (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Legend Biotech (Inst); Roche (Inst); Secura Bio (Inst); Takeda (Inst)
Research Funding - 2Seventy bio (Inst); Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Amgen (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); CARsgen Therapeutics (Inst); Cartesian Therapeutics (Inst); Celgene (Inst); Celularity (Inst); crispr therapeutics (Inst); EMD Serono (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ichnos Sciences (Inst); Incyte (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); poseida therapeutics (Inst); Sanofi (Inst); Takeda (Inst); Teva (Inst)
 
Paul G. Richardson
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Karyopharm Therapeutics; Novartis; Oncopeptides; Sanofi; Secura Bio; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Karyopharm Therapeutics (Inst); Oncopeptides (Inst); Takeda (Inst)
 
Margee Kyada
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Shuyu Chu
Employment - BeiGene; Bristol-Myers Squibb
Stock and Other Ownership Interests - Abbvie (I); BeiGene; Bristol-Myers Squibb; Johnson & Johnson (I)
Travel, Accommodations, Expenses - BeiGene; Bristol-Myers Squibb
 
Min Chen
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Patricia C. Abad
Employment - Bristol-Myers Squibb; Clarapath (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Clarapath (I); Siemens (I)
 
Juliane Morando
Employment - Bristol-Myers Squibb; Novartis
Stock and Other Ownership Interests - Bristol-Myers Squibb; Novartis
 
Niels W.C.J. van de Donk
Consulting or Advisory Role - Adaptive Biotechnologies (Inst); Amgen (Inst); Bayer (Inst); Bristol Myers Squibb Foundation (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst); Takeda (Inst)
Research Funding - Amgen (Inst); Bristol Myers Squibb Foundation (Inst); Celgene (Inst); Cellectis (Inst); Janssen (Inst); Novartis (Inst)